|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
Ellsworth RE, Blackburn HL, Shriver CD,
Soon-Shiong P and Ellsworth DL: Molecular heterogeneity in breast
cancer: State of the science and implications for patient care.
Semin Cell Dev Biol. 64:65–72. 2017. View Article : Google Scholar
|
|
3
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Slamon DJ, Godolphin W, Jones LA, Holt JA,
Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al:
Studies of the HER-2/neu proto-oncogene in human breast and ovarian
cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vogel CL, Cobleigh MA, Tripathy D, Gutheil
JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF,
Burchmore M, et al: Efficacy and safety of trastuzumab as a single
agent in first-line treatment of HER2-overexpressing metastatic
breast cancer. J Clin Oncol. 20:719–726. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Baselga J, Carbonell X, Castañeda-Soto NJ,
Clemens M, Green M, Harvey V, Morales S, Barton C and Ghahramani P:
Phase II study of efficacy, safety, and pharmacokinetics of
trastuzumab monotherapy administered on a 3-weekly schedule. J Clin
Oncol. 23:2162–2171. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Marty M, Cognetti F, Maraninchi D, Snyder
R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A,
et al: Randomized phase II trial of the efficacy and safety of
trastu-zumab combined with docetaxel in patients with human
epidermal growth factor receptor 2-positive metastatic breast
cancer administered as first-line treatment: The M77001 study
group. J Clin Oncol. 23:4265–4274. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
et al: Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun Z, Shi Y, Shen Y, Cao L, Zhang W and
Guan X: Analysis of different HER-2 mutations in breast cancer
progression and drug resistance. J Cell Mol Med. 19:2691–2701.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pinto AE, André S, Pereira T, Nóbrega S
and Soares J: C-erbB-2 oncoprotein overexpression identifies a
subgroup of estrogen receptor positive (ER+) breast cancer patients
with poor prognosis. Ann Oncol. 12:525–533. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bauer KR, Brown M, Cress RD, Parise CA and
Caggiano V: Descriptive analysis of estrogen receptor
(ER)-negative, progesterone receptor (PR)-negative, and
HER2-negative invasive breast cancer, the so-called triple-negative
phenotype: A population-based study from the California cancer
Registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dawood S, Broglio K, Kau SW, Green MC,
Giordano SH, Meric-Bernstam F, Buchholz TA, Albarracin C, Yang WT,
Hennessy BT, et al: Triple receptor-negative breast cancer: The
effect of race on response to primary systemic treatment and
survival outcomes. J Clin Oncol. 27:220–226. 2009. View Article : Google Scholar
|
|
14
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Z, Gerstein M and Snyder M: RNA-seq:
A revolutionary tool for transcriptomics. Nat Rev Genet. 10:57–63.
2009. View Article : Google Scholar
|
|
16
|
Liu T, Yu N, Ding F, Wang S, Li S, Zhang
X, Sun X, Chen Y and Liu P: Verifying the markers of ovarian cancer
using RNA-seq data. Mol Med Rep. 12:1125–1130. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li B and Dewey CN: RSEM: Accurate
transcript quantification from RNA-Seq data with or without a
reference genome. BMC Bioinformatics. 12:3232011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li H and Durbin R: Fast and accurate short
read alignment with Burrows-Wheeler transform. Bioinformatics.
25:1754–1760. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Audic S and Claverie JM: The significance
of digital gene expression profiles. Genome Res. 7:986–995. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Beissbarth T and Speed TP: GOstat: Find
statistically over-represented Gene Ontologies within a group of
genes. Bioinformatics. 20:1464–1465. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mao X, Cai T, Olyarchuk JG and Wei L:
Automated genome annotation and pathway identification using the
KEGG orthology (KO) as a controlled vocabulary. Bioinformatics.
21:3787–3793. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
23
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li W, Ma H, Zhang J, Zhu L, Wang C and
Yang Y: Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem
cell markers in tumorigenesis and metastasis. Sci Rep. 7:138562017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shao J, Fan W, Ma B and Wu Y: Breast
cancer stem cells expressing different stem cell markers exhibit
distinct biological characteristics. Mol Med Rep. 14:4991–4998.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yin H and Glass J: The phenotypic
radiation resistance of CD44+/CD24(-or low) breast cancer cells is
mediated through the enhanced activation of ATM signaling. PLoS
One. 6:pp. e240802011, View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang J, Kinoh H, Hespel L, Liu X, Quader
S, Martin J, Chida T, Cabral H and Kataoka K: Effective treatment
of drug resistant recurrent breast tumors harboring cancer
stem-like cells by stau-rosporine/epirubicin co-loaded polymeric
micelles. J Control Release. 264:127–135. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Puchinskaya MV: Cancer stem cell markers
and their prognostic value. Arkh Patol. 78:47–54. 2016.In Russian.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ginestier C, Hur MH, Charafe-Jauffret E,
Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, et al: ALDH1 is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell
Stem Cell. 1:555–567. 2007. View Article : Google Scholar
|
|
30
|
Kimura O, Takahashi T, Ishii N, Inoue Y,
Ueno Y, Kogure T, Fukushima K, Shiina M, Yamagiwa Y, Kondo Y, et
al: Characterization of the epithelial cell adhesion molecule
(EpCAM)+ cell population in hepatocellular carcinoma cell lines.
Cancer Sci. 101:2145–2155. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fodde R and Brablet T: Wnt/beta-catenin
signaling in cancer stemness and malignant behavior. Curr Opin Cell
Biol. 19:150–158. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Androutsellis-Theotokis A, Leker RR,
Soldner F, Hoeppner DJ, Ravin R, Poser SW, Rueger MA, Bae SK,
Kittappa R and McKay RD: Notch signalling regulates stem cell
numbers in vitro and in vivo. Nature. 442:823–826. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Valenti G, Quinn HM, Heynen GJJE, Lan L,
Holland JD, Vogel R, Wulf-Goldenberg A and Birchmeier W: Cancer
stem cells regulate cancer-associated fibroblasts via activation of
Hedgehog signaling in mammary gland tumors. Cancer Res.
77:2134–2147. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Daynac M, Tirou L, Faure H, Mouthon MA,
Gauthier LR, Hahn H, Boussin FD and Ruat M: Hedgehog controls
quiescence and activation of neural stem cells in the adult
ventricular-subventricular zone. Stem Cell Reports. 7:735–748.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sakaki-Yumoto M, Katsuno Y and Derynck R:
TGF-β family signaling in stem cells. Biochim Biophys Acta.
1830:2280–2296. 2013. View Article : Google Scholar
|
|
36
|
Zhang J, Lai W, Li Q, Yu Y, Jin J, Guo W,
Zhou X, Liu X and Wang Y: A novel oncolytic adenovirus targeting
Wnt signaling effectively inhibits cancer-stem like cell growth via
metastasis, apoptosis and autophagy in HCC models. Biochem Biophys
Res Commun. 491:469–477. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Khramtsov AI, Khramtsova GF, Tretiakova M,
Huo D, Olopade OI and Goss KH: Wnt/beta-catenin pathway activation
is enriched in basal-like breast cancers and predicts poor outcome.
Am J Pathol. 176:2911–2920. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li T, Zhang L and Huo X: Inhibitory
effects of aesculetin on the proliferation of colon cancer cells by
the Wnt/β-catenin signaling pathway. Oncol Lett. 15:7118–7122.
2018.PubMed/NCBI
|
|
39
|
Medeiros PJ and Jackson DN: Neuropeptide Y
Y5-receptor activation on breast cancer cells acts as a paracrine
system that stimulates VEGF expression and secretion to promote
angiogenesis. Peptides. 48:106–113. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang Y, Meng X, Zeng H, Guan Y, Zhang Q,
Guo S, Liu X and Guo Q: Serum vascular endothelial growth factor-C
levels: A possible diagnostic marker for lymph node metastasis in
patients with primary non-small cell lung cancer. Oncol Lett.
6:545–549. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Saharinen P, Eklund L, Pulkki K, Bono P
and Alitalo K: VEGF and angiopoietin signaling in tumor
angiogenesis and metastasis. Trends Mol Med. 17:347–362. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Clarke MF, Dick JE, Dirks PB, Eaves CJ,
Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer
stem cells-perspectives on current status and future directions:
AACR Workshop on cancer stem cells. Cancer Res. 66:9339–9344. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Okamoto OK and Perez JF: Targeting cancer
stem cells with monoclonal antibodies: A new perspective in cancer
therapy and diagnosis. Expert Rev Mol Diagn. 8:387–393. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Phillips TM, McBride WH and Pajonk F: The
response of CD24(-/low)/CD44+ breast cancer-initiating cells to
radiation. J Natl Cancer Inst. 98:1777–1785. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sottoriva A, Verhoeff JJ, Borovski T,
McWeeney SK, Naumov L, Medema JP, Sloot PM and Vermeulen L: Cancer
stem cell tumor model reveals invasive morphology and increased
phenotypical heterogeneity. Cancer Res. 70:46–56. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Marcato P, Dean CA, Giacomantonio CA and
Lee PW: Aldehyde dehydrogenase: Its role as a cancer stem cell
marker comes down to the specific isoform. Cell Cycle.
10:1378–1384. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yamashita T, Ji J, Budhu A, Forgues M,
Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, et al:
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating
cells with stem/progenitor cell features. Gastroenterology.
136:1012–1024. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Watt SM and Chan JY: CD164-a novel
sialomucin on CD34+ cells. Leuk Lymphoma. 37:1–25. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lee YN, Kang JS and Krauss RS:
Identification of a role for the sialomucin CD164 in myogenic
differentiation by signal sequence trapping in yeast. Mol Cell
Biol. 21:7696–7706. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lin J, Xu K, Wei J, Heimberger AB, Roth JA
and Ji L: MicroRNA-124 suppresses tumor cell proliferation and
invasion by targeting CD164 signaling pathway in non-small cell
lung cancer. J Gene Ther. 2:62016.PubMed/NCBI
|
|
51
|
Tang J, Zhang L, She X, Zhou G, Yu F,
Xiang J and Li G: Inhibiting CD164 expression in colon cancer cell
line HCT116 leads to reduced cancer cell proliferation, mobility,
and metastasis in vitro and in vivo. Cancer Invest. 30:380–389.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wong PF and Abubakar S: Comparative
transcriptional study of the effects of high intracellular zinc on
prostate carcinoma cells. Oncol Rep. 23:1501–1516. 2010.PubMed/NCBI
|
|
53
|
Coustan-Smith E, Song G, Clark C, Key L,
Liu P, Mehrpooya M, Stow P, Su X, Shurtleff S, Pui CH, et al: New
markers for minimal residual disease detection in acute
lymphoblastic leukemia. Blood. 117:6267–6276. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chirumbolo S: CD164 and other recently
discovered activation markers as promising tools for allergy
diagnosis: What's new? Clin Exp Med. 11:255–257. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Arendt LM, Rudnick JA, Keller PJ and
Kuperwasser C: Stroma in breast development and disease. Semin Cell
Dev Biol. 21:11–18. 2010. View Article : Google Scholar :
|
|
56
|
Thiery JP and Sleeman JP: Complex networks
orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell
Biol. 7:131–142. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
He ZY, Wu SG, Peng F, Zhang Q, Luo Y, Chen
M and Bao Y: Up-regulation of RFC3 promtes triple negative breast
cancer metastasis and is associated with poor prognosis via EMT.
Transl Oncol. 10:1–9. 2017. View Article : Google Scholar
|
|
58
|
Ajani JA, Song S, Hochster HS and
Steinberg IB: Cancer stem cells: The promise and the potential.
Semin Oncol. 42(Suppl 1): pp. S3–S17. 2015, View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Germano G, Allavena P and Mantovani A:
Cytokines as a key component of cancer-related inflammation.
Cytokine. 43:374–379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Nagarsheth N, Wicha MS and Zou W:
Chemokines in the cancer microenvironment and their relevance in
cancer immunotherapy. Nat Rev Immunol. 17:559–572. 2017. View Article : Google Scholar : PubMed/NCBI
|
